Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor — GA-9  

Acromegaly Due to Pituitary Adenoma Clinical Trial

Official title: Modulating the Glucose-dependent Insulinotropic Polypeptide (GIP) System in Patients With Acromegaly Due to a Pituitary Tumor

Status Completed

Clinical Trial Summary

Modulation of the GIP System in Patients With Acromegaly Due to a Pituitary adenoma

Clinical Trial Description

Aim: To determine the importance of the GIP system in patients with acromegaly who has paradoxical growth hormone secretion during an oral glucose tolerance test (OGTT) using a GIP antagonist (GIP-A). Thirty participants (age 18-75 years) with normal kidney and liver parameters and hemoglobin levels will be included in a placebo-controlled cross-over study. The study consists of two study days with concomitant infusions of A) GIP-A or B) saline (placebo). A paradoxical growth hormone secretion to an OGTT is here defined as an increase in plasma growth hormone levels of ≥30% from baseline based on a mean value of the definitions in the literature. Regazzo et al. (2017) European Journal of Endocrinology 176, 543-553 Mukai et al. (2018) The Journal of Clinical Endocrinology and Metabolism 104(5), 1637-1644 Hage et al. (2019) The Journal of Clinical Endocrinology and Metabolism 104(5), 1777-1787 Scaroni et al. (2019) J Clin Endocrinol Metab 104(3), 856-862 ;

Related Conditions & MeSH terms

• Acromegaly
• Acromegaly Due to Pituitary Adenoma
• Adenoma
• Growth Hormone-Secreting Pituitary Adenoma
• Pituitary Diseases
• Pituitary Neoplasms

• NCT number: NCT03807076
• Study type: Interventional
• Source: University of Copenhagen
• Status: Completed
• Phase: N/A
• Start date: August 13, 2019
• Completion date: November 28, 2023